SMART Mobile Application Technology Utilization in the Treatment of Sickle Cell Disease Post Day Hospital Discharge
Sickle Cell Disease
About this trial
This is an interventional supportive care trial for Sickle Cell Disease focused on measuring Sickle Cell Disease
Eligibility Criteria
Inclusion Criteria:
- documented Hgb SS, SC, or HgbS-beta0 thalassemia
- age 18 years old or older
- seen during an acute care visit at the Duke Day Hospital
Exclusion Criteria:
- incapable of giving informed consent
- greater than 20 acute care visits within the past year
- patients on chronic RBC transfusions (scheduled transfusions)
- patients admitted to the hospital from the day hospital
Sites / Locations
- Duke University Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
SMART app
Standard of care control group
SMART, a mobile phone-based self-monitoring service to enhance outpatient treatment in chronic illness will be tested for its utility to help reduce acute care utilization rates for patients given SMART following acute care visits at the Sickle Cell Day Hospital. SMART will enable symptom monitoring with a particular emphasis on pain measures, co-symptoms, and related interventions aided by provider daily monitoring and support guided by patient report via SMART to provide a Sickle Cell Disease Information interchange (SCDi) service. Instead of using their current routine of triaging phone messages daily, assessing patients' need for intervention, providers will instead monitor patients' entries via SMART daily.
The control group will get standard of care, including a printed plan for medications to be taken, phone number to call for questions or issues, and the return date for visit